SAN DIEGO, Feb. 13, 2017 /PRNewswire/ -- MabVax Therapeutics
Holdings, Inc. (NASDAQ: MBVX), a clinical stage immuno-oncology
drug development company, today announced results from a
pre-clinical study evaluating the potential benefits of using
MabVax's HuMab-5B1antibody, MVT-5873, currently in Phase I clinical
trials for the treatment of metastatic pancreatic cancer with
Halozyme Therapeutic's (NASDAQ: HALO) investigational drug PEGPH20,
which targets the tumor microenvironment potentially allowing
increased access of co-administered cancer drug therapies to solid
tumors. PEGPH20 is currently in phase III clinical
development for metastatic pancreatic cancer and in phase I
clinical trials for non-small cell lung cancer, gastric cancer, and
metastatic breast cancer.
Results from the preclinical study were positive demonstrating
improvement in accumulation of MVT-5873 on tumors in an animal
model of pancreatic cancer when administered in sequence with
PEGPH20.
"Initiating preclinical investigations of MVT-5873 in
combination with Halozyme's PEGPH20 provides a new potential
treatment strategy combining the tumor penetration ability of
PEGPH20 with the anti-tumor effects of MVT-5873," stated President
and Chief Executive Officer J. David
Hansen. "The initial pre-clinical collaboration
combining our antibody with Halozyme's unique therapy was
encouraging and more comprehensive pre-clinical studies will now be
undertaken. The potential of combining MVT-5873 with PEGPH20 could
represent a significant step forward in the fight against
pancreatic cancer. The results of these investigations will provide
insight into broader applications of the PEGPH20 technology to
other HuMab-5B1 programs including the Company's immuno-PET imaging
agent MVT-2163 that is also in phase I clinical trials, and the
radioimmunotherapy product MVT-1075 that is planned for clinical
evaluation early this year."
About MVT-5873
MVT-5873 is currently in a phase I
clinical trial that is designed to establish safety and determine
the recommended phase II dose both as monotherapy, and in
combination with a standard of care chemotherapy using
nab-paclitaxel plus gemcitabine. MabVax recently reported
that the safety of MVT-5873 had been established at three
incremental dose levels which was determined to be sufficient
according to the protocol for investigators to begin enrolling and
dosing patients with previously untreated pancreatic cancer
receiving a standard of care chemotherapy.
About MabVax
MabVax Therapeutics Holdings, Inc. is a
clinical-stage biotechnology company focused on the development of
antibody-based products to address unmet medical needs in the
treatment of cancer. MabVax has discovered a pipeline of
human monoclonal antibody products based on the protective immune
responses generated by patients who have been vaccinated against
targeted cancers with the Company's proprietary vaccines.
MabVax's HuMab-5B1 antibody is fully human and was discovered from
the immune response of cancer patients vaccinated with an
antigen-specific vaccine during a Phase I trial at Memorial Sloan
Kettering Cancer Center. The antigen the antibody
targets is expressed on more than 90% of pancreatic cancers, making
the antibody potentially broadly applicable to most patients
suffering from this type of cancer. MabVax is
headquartered in San Diego. Additional information is
available at www.mabvax.com.
Safe Harbor Statement Related to MabVax
The statements
set forth above include forward-looking statements regarding
matters that are not historical facts, including statements
relating to the company's progress in its phase I clinical trial of
MVT-5873. MabVax can make no assurance that all of the
product development pipeline will be fully developed by the
company. Because such statements are subject to risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements.
Words such as "anticipates," "plans," "expects," "intends," "will,"
"potential," "hope" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon current expectations of the company and
involve assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could
differ materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties.
Detailed information regarding factors that may cause actual
results to differ materially from the results expressed or implied
by statements in this press release relating to the company may be
found in the company's periodic filings with the Securities and
Exchange Commission, including the factors described in the section
entitled "Risk Factors" in its most recent Annual and Quarterly
Reports filed with the Securities and Exchange Commission.
The company does not undertake any obligation to update
forward-looking statements contained in this press release.
MabVax Contacts:
Investor Relations:
Greg
Hanson, CFO
858-500-8457
David Hansen, President and
CEO
858-500-8455
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mabvax-therapeutics-studies-lead-investigational-drug-mvt-5873-with-halozyme-pegph20-300405877.html
SOURCE MabVax Therapeutics